Terms: = Brain cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Clinical Outcome
6 results:
1. TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R; Madureira PA; Ferreira B; Baptista I; Machado S; Colaço L; Dos Santos M; Liu N; Dopazo A; Ugurel S; Adrienn A; Kiss-Toth E; Isbilen M; Gure AO; Link W
Nat Commun; 2017 Mar; 8():14687. PubMed ID: 28276427
[TBL] [Abstract] [Full Text] [Related]
2. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract] [Full Text] [Related]
3. Meningioma: an update.
Lusis E; Gutmann DH
Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemical markers for prognosis of cerebral glioblastomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
[TBL] [Abstract] [Full Text] [Related]
6. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, mdm2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract] [Full Text] [Related]
